415 related articles for article (PubMed ID: 30128659)
1. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.
Stieb S; Eleftheriou A; Warnock G; Guckenberger M; Riesterer O
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2201-2217. PubMed ID: 30128659
[TBL] [Abstract][Full Text] [Related]
2.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
3. 18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma.
Mapelli P; Picchio M
Int J Biol Markers; 2020 Feb; 35(1_suppl):42-46. PubMed ID: 32079461
[TBL] [Abstract][Full Text] [Related]
4. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode.
Mortensen LS; Buus S; Nordsmark M; Bentzen L; Munk OL; Keiding S; Overgaard J
Acta Oncol; 2010 Oct; 49(7):934-40. PubMed ID: 20831480
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
[TBL] [Abstract][Full Text] [Related]
6. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review.
Halmos GB; Bruine de Bruin L; Langendijk JA; van der Laan BF; Pruim J; Steenbakkers RJ
Clin Nucl Med; 2014 Jan; 39(1):44-8. PubMed ID: 24152663
[TBL] [Abstract][Full Text] [Related]
7. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.
Bache M; Kappler M; Said HM; Staab A; Vordermark D
Curr Med Chem; 2008; 15(4):322-38. PubMed ID: 18288988
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia as a Biomarker and for Personalized Radiation Oncology.
Vordermark D; Horsman MR
Recent Results Cancer Res; 2016; 198():123-42. PubMed ID: 27318684
[TBL] [Abstract][Full Text] [Related]
9.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
10. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging of Tumor Hypoxia in Head and Neck Cancer: A Primer for Neuroradiologists.
Khan R; Seltzer M
Neuroimaging Clin N Am; 2020 Aug; 30(3):325-339. PubMed ID: 32600634
[TBL] [Abstract][Full Text] [Related]
12. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
13. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
14.
De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
[TBL] [Abstract][Full Text] [Related]
16. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
[TBL] [Abstract][Full Text] [Related]
17. FMISO as a Biomarker for Clinical Radiation Oncology.
Zschaeck S; Steinbach J; Troost EG
Recent Results Cancer Res; 2016; 198():189-201. PubMed ID: 27318688
[TBL] [Abstract][Full Text] [Related]
18. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
[TBL] [Abstract][Full Text] [Related]
19. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
